CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishPrognosis for unresectable canine malignant melanoma (MM) is typically poor, and therapeutic approaches remain largely palliative. A bi-institutional trial was conducted to compare efficacy and safety of radiation therapy (RT) and RT with post-radiation temozolomide in dogs with chemotherapy-naive, measurable MM. RT consisted of 5 x 6 Gy fractions over 2.5weeks. Dogs whose owners wished to pursue chemotherapy received adjuvant oral temozolomide (60 mg m(-2) for 5 days every 28 days). Fifteen dogs were treated with RT only (Group 1) and 12 dogs subsequently received temozolomide (Group 2). Overall response rate was similar between Group 1 (86.7%) and Group 2 (81.1%). Median time to progression (TTP) was significantly longer in Group 2 (205 days) compared to Group 1 (110 days; p=0.046). Survival time was not significantly different between groups. Both treatments were well tolerated. Post-radiation temozolomide has a good safety profile, and may improve TTP in MM when compared to coarse fractionated RT.
| Titolo: | Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma |
| Autore/i: | Cancedda S.; Rohrer Bley C.; Aresu L.; Dacasto M.; Leone V. F.; Pizzoni S.; Gracis M.; Marconato L. |
| Autore/i Unibo: | |
| Anno: | 2016 |
| Rivista: | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1111/vco.12122 |
| Abstract: | Prognosis for unresectable canine malignant melanoma (MM) is typically poor, and therapeutic approaches remain largely palliative. A bi-institutional trial was conducted to compare efficacy and safety of radiation therapy (RT) and RT with post-radiation temozolomide in dogs with chemotherapy-naive, measurable MM. RT consisted of 5 x 6 Gy fractions over 2.5weeks. Dogs whose owners wished to pursue chemotherapy received adjuvant oral temozolomide (60 mg m(-2) for 5 days every 28 days). Fifteen dogs were treated with RT only (Group 1) and 12 dogs subsequently received temozolomide (Group 2). Overall response rate was similar between Group 1 (86.7%) and Group 2 (81.1%). Median time to progression (TTP) was significantly longer in Group 2 (205 days) compared to Group 1 (110 days; p=0.046). Survival time was not significantly different between groups. Both treatments were well tolerated. Post-radiation temozolomide has a good safety profile, and may improve TTP in MM when compared to coarse fractionated RT. |
| Data stato definitivo: | 2019-10-15T22:37:48Z |
| Appare nelle tipologie: |
File in questo prodotto:
Copyright © 2021